United Therapeutics (UTHR) Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last twelve months. There are currently 2 sell ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" UTHR shares.
View UTHR analyst ratings or view top-rated stocks.

9 analysts have issued 1-year target prices for United Therapeutics' stock. Their UTHR share price forecasts range from $230.00 to $375.00. On average, they expect the company's share price to reach $294.67 in the next twelve months. This suggests a possible upside of 41.2% from the stock's current price.
View analysts price targets for UTHR or view top-rated stocks among Wall Street analysts.

United Therapeutics' stock was trading at $278.09 at the beginning of 2023. Since then, UTHR shares have decreased by 24.9% and is now trading at $208.71.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our UTHR earnings forecast.

United Therapeutics Co. (NASDAQ:UTHR) released its quarterly earnings results on Wednesday, May, 3rd. The biotechnology company reported $4.86 earnings per share for the quarter, beating analysts' consensus estimates of $4.26 by $0.60. The biotechnology company earned $506.90 million during the quarter, compared to the consensus estimate of $514.37 million. United Therapeutics had a net margin of 36.76% and a trailing twelve-month return on equity of 15.49%. United Therapeutics's quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter last year, the firm earned $5.03 EPS.

ETFs with the largest weight of United Therapeutics (NASDAQ:UTHR) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), Formidable Fortress ETF (KONG), The Acquirers Fund (ZIG), Invesco Dynamic Pharmaceuticals ETF (PJP), First Trust NYSE Arca Biotechnology Index Fund (FBT), Subversive Mental Health ETF (SANE), AdvisorShares Dorsey Wright Alpha Equal Weight ETF (DWEQ) and Inspire Faithward Mid Cap Momentum ETF (GLRY).

64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

United Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.14%), Wellington Management Group LLP (8.07%), Avoro Capital Advisors LLC (6.13%), FMR LLC (5.42%), Renaissance Technologies LLC (4.75%) and State Street Corp (3.83%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon and Raymond Dwek.
View institutional ownership trends.

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of UTHR stock can currently be purchased for approximately $208.71.

United Therapeutics (NASDAQ:UTHR) has a market capitalization of $9.78 billion and generates $1.94 billion in revenue each year. The biotechnology company earns $727.30 million in net income (profit) each year or $14.85 on an earnings per share basis.

The company employs 965 workers across the globe.

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The official website for the company is www.unither.com. The biotechnology company can be reached via phone at (301) 608-9292, via email at ir@unither.com, or via fax at 301-608-9291.